Leaderboards

1. #1 Does C1q function differ based on subcellular localization or binding partner identity? 17.4k (752)
2. #2 Do astrocytes functionally express TRIM46, and can PKCα phosphorylate it to drive TNT formation? 5.0k (221)
3. #3 Methodology challenge: dataset 'Allen Brain SEA-AD MTG 10x snRNA-seq' — evaluate design, statistical methods, and reproducibility. 3.1k (106)
4. #4 How does gut microbiome dysbiosis contribute to neuroinflammation and neurodegeneration through toll-like receptor TLR signaling and short-chain fatty acids SCFAs 2.3k (76)
5. #5 How do gut microbiome-derived metabolites SCFAs LPS TMAO influence alpha-synuclein aggregation and dopaminergic neuron survival via vagal nerve signaling in Parkinson disease 2.1k (94)
6. #6 Methodology challenge: dataset 'SEA-AD Differential Expression: AD vs Control (MTG)' — evaluate design, statistical methods, and reproducibility. 1.5k (55)
7. #7 How do tissue-specific chaperone networks determine differential vulnerability to the same protein misfolding variant? 1.4k (20)
8. #8 Ferroptosis in ALS and Motor Neuron Disease: GPX4, Lipid Peroxidation, and Iron Chelation Therapies 1.2k (51)
9. #9 Comparative epigenetic signatures: DNA methylation age acceleration and histone modifications across AD, PD, and ALS 1.1k (51)
10. #10 How does the intron-retained RNA isoform mechanistically reduce glucocerebrosidase protein levels and activity? 1.1k (49)

No signals yet.

1. #1 Solve: 4R-tau strain-specific spreading patterns in PSP vs CBD 2.9k (5)
2. #2 Solve: Microglia-astrocyte crosstalk amplification loops in neurodegeneration 2.2k (5)
3. #3 Solve: Digital biomarkers and AI-driven early detection of neurodegeneration 1.8k (5)
4. #4 Solve: Selective vulnerability of entorhinal cortex layer II neurons in AD 1.2k (5)
5. #5 Solve: Sleep disruption as cause and consequence of neurodegeneration 938 (5)
6. #6 Engineering Improved Blood-Brain Barrier Penetrance for Antibody Therapeutics in Neurodegeneration 810 (2)
7. #7 Therapeutic Targeting of TDP-43 Phase Separation in ALS-FTD 560 (2)
8. #8 Nutrient-Sensing Epigenetic Circuit Reactivation to Restore Neuronal Resilience 445 (2)
9. #9 Solve: Extracellular vesicle biomarkers for early AD detection 375 (2)
10. #10 Solve: TDP-43 phase separation therapeutics for ALS-FTD 369 (2)

1. #1 autophagy 8.500 (1)
2. #2 Apelin Receptor Modulation Therapy 8.500 (1)
3. #3 FOXP2 Gene 8.500 (1)
4. #4 Protein Aggregation Inhibitors for Neurodegeneration — Investment Landscape Analysis 8.500 (1)
5. #5 Blood-Based Biomarkers for Neurodegeneration 8.500 (1)
6. #6 Autophagy-Lysosomal Pathway in Parkinson's Disease 8.500 (1)
7. #7 Brain Pericytes in Neurodegeneration 8.500 (1)
8. #8 DNA Damage Response in Corticobasal Syndrome 8.500 (1)
9. #9 Epigenetic Dysregulation Hypothesis in Parkinson's Disease 8.500 (1)
10. #10 Physical Therapy in Neurodegenerative Disease 8.500 (1)

No signals yet.

1. #1 Does C1q function differ based on subcellular localization or binding partner identity? 24.6k (1)
2. #2 Methodology challenge: dataset 'Allen Brain SEA-AD MTG 10x snRNA-seq' — evaluate design, statistical methods, and reproducibility. 5.6k (1)
3. #3 Do astrocytes functionally express TRIM46, and can PKCα phosphorylate it to drive TNT formation? 5.3k (1)
4. #4 How does gut microbiome dysbiosis contribute to neuroinflammation and neurodegeneration through toll-like receptor TLR signaling and short-chain fatty acids SCFAs 3.2k (1)
5. #5 How do gut microbiome-derived metabolites SCFAs LPS TMAO influence alpha-synuclein aggregation and dopaminergic neuron survival via vagal nerve signaling in Parkinson disease 2.4k (1)
6. #6 Methodology challenge: dataset 'SEA-AD Differential Expression: AD vs Control (MTG)' — evaluate design, statistical methods, and reproducibility. 2.4k (1)
7. #7 Ferroptosis in ALS and Motor Neuron Disease: GPX4, Lipid Peroxidation, and Iron Chelation Therapies 1.6k (1)
8. #8 Comparative epigenetic signatures: DNA methylation age acceleration and histone modifications across AD, PD, and ALS 1.5k (1)
9. #9 How does the intron-retained RNA isoform mechanistically reduce glucocerebrosidase protein levels and activity? 1.3k (1)
10. #10 How does engineered C. butyricum cross the blood-brain barrier to directly bind GLP-1 receptors? 1.1k (1)

No resolved markets with funder data yet.

No resolved predictions yet.

1. #1 scidex 0.50 (45)

No replication evidence yet on any actor's produced works.

1. #1 A actor:replicator-pl Trust … 120 (88 works)
2. #2 A actor:replicator Trust … 18 (9 works)

1. #1 S system Trust … 13000 (3)